BioTech 365

MARCH 2, 2021

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical License to Nobel prize winning CRISPR technology supports internal research and development DUBLIN, Ireland–(BUSINESS WIRE)–ERS Genomics Limited, which was formed … Continue reading (..)

Gene Editing 40

Gene Editing Genomics Genome Licensing 40

BioTech 365

JUNE 30, 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagents offering DUBLIN & TOKYO–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad … Continue reading →

Genomics 40

Genomics Genome Licensing Licensing 40

BioTech 365

JULY 26, 2021

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models DUBLIN & SHIZUOKA, Japan–(BUSINESS WIRE)–ERS Genomics Limited, … Continue reading →

Genomics 40

Genomics Genome Licensing Licensing 40

BioTech 365

APRIL 19, 2021

ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement CRISPR offerings to enhance NUVISAN’s drug development service portfolio DUBLIN & BERLIN–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access … Continue reading →

Genomics 40

Genomics Genome Licensing Licensing 40

BioTech 365

MAY 12, 2021

ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement License agreement to enhance GenScript’s CRISPR offering for gene and cell therapy research DUBLIN & PISCATAWAY, N.J.–(BUSINESS

Genomics 40

Genomics Genome Licensing Licensing 40

BioTech 365

AUGUST 17, 2021

ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology DUBLIN & … Continue (..)

Engineer 40

Engineer Genomics Genome Licensing 40

BioTech 365

MARCH 9, 2021

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models DUBLIN & TOKUSHIMA, Japan–(BUSINESS WIRE)–ERS … Continue reading →

Genomics 40

Genomics Genome Licensing Licensing 40

BioPharma Reporter

DECEMBER 3, 2020

ERS Genomics, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by the one of the joint 2020 Nobel Prize winners for Chemistry, Dr Emmanuelle Charpentier, has granted a non-exclusive license agreement to German startup, Vivlion.

Licensing 64

Licensing Licensing Genome Genomics 64

BioTech 365

FEBRUARY 23, 2021

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →

Life Science 40

Life Science Genomics Genome Licensing 40

BioSpace

SEPTEMBER 8, 2021

based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans. Durham, N.C.-based

Genomics 70

Genomics Genome Licensing Licensing 70

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

pharmaphorum

MARCH 24, 2022

LifeMine has developed an industrialised, genomics-based discovery engine that it hopes will take a broad, systematic approach to identifying new compounds from fungi and screening them for activity against disease targets. Image by jggrz from Pixabay . The post GSK partners LifeMine on fungi-derived medicines appeared first on.

Medicine 105

Medicine Genomics Genome Engineer 105

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks.

Development 242

Development Bioequivalency Generic Drugs Production 242

BioTech 365

MARCH 1, 2021

ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development Jon Kratochvil joins as Vice President for Business Development & Licensing for North America … Continue reading →

Business Development 40

Business Development Genomics Genome Development 40

Pharmaceutical Technology

JULY 22, 2022

In 2020, Sangamo and Novartis signed an exclusive, global licensing collaboration agreement to develop and commercialise genomic therapies for the treatment of neurodevelopmental disorders, including autism. The post Sangamo’s cell therapy receives EC orphan medicinal product designation appeared first on Pharmaceutical Technology.

Medicine 130

Medicine Production Genomics Genome 130

BioTech 365

OCTOBER 13, 2020

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genomics 40

Genomics Genome Reagent Gene Editing 40

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 40

Licensing Licensing Genome Genomics 40

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. Under the agreement, Boehringer Ingelheim has the option to license dark antigens discovered and validated by Enara Bio.

Genomics 80

Genomics Genome Licensing Licensing 80

Pharmaceutical Technology

FEBRUARY 26, 2023

Although research here is about 20 years old, it remains new compared to other areas like genomics, says Gilbert. Previously, Takeda had licensed the two Finch treatments FIN-524 and FIN-525 for their development in IBD. Last year, Takeda Pharmaceutical ended its deal with Finch in August after a review of its pipeline.

Bacteria 278

Bacteria Trials Research Medicine 278

pharmaphorum

DECEMBER 2, 2021

GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicines. Most notable is GSK’s $700 million upfront deal in the summer to license two drugs for neurological disease developed by US biotech Alector.

Biobanking 93

Biobanking Genomics Genome Genetics 93

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

JANUARY 12, 2021

Boehringer Ingelheim has announced it has signed a collaboration and licensing deal with Enara Bio to advance novel targeted cancer immunotherapies. Dark Antigens are in reference to a newer class of cancer antigens derived from a portion of the human genome not normally expressed as a protein. Michael Vi/Shutterstock.

Research 52

Research Genomics Genome Licensing 52

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. Nonetheless, Moderna has previously been involved in licensing deals to advance its technology. Biotech Moderna, Inc. have announced they have entered into a definitive agreement for Moderna to acquire OriCiro at a cost of $85 million. The deal marks 10-year-old Moderna’s first acquisition.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

Pharmaceutical Technology

AUGUST 26, 2008

” Today most big pharmaceutical companies are pursuing biotechnology either in house or by using an in-licensing strategy. Staples said it expects to continue growing its portfolio across a range of technologies through M&A, partnering and in-licensing.

Antibody 100

Antibody Licensing Licensing Production 100

pharmaphorum

DECEMBER 5, 2022

That sets up a rolling Biologics License Application (BLA) with the FDA by the end of the year, setting Valneva on course to bring the first chikungunya vaccine to market anywhere in the world. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccine 98

Vaccine Vaccination Antibody Allergies 98

pharmaphorum

FEBRUARY 11, 2022

” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.

Gene Therapy 111

Gene Therapy Gene Trials FDA Approval 111

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

MARCH 25, 2021

The COSMIC (Catalogue of Somatic Mutations in Cancer) database, operated by the Wellcome Sanger Institute, grew out of the work of the Cancer Genome Project and has been gathering data on mutations associated with specific cancers for almost 17 years.

Drugs 59

Drugs Genome Project Genomics Genome 59

pharmaphorum

JULY 14, 2022

“We must, however, recognise the unacceptably difficult journey to get to this point for those affected; ten agonising months since Trodelvy was licensed by the MHRA,” said the patient organisation’s chief executive Baroness Delyth Morgan.

Drugs 104

Drugs Hormones Genomics Genome 104

pharmaphorum

DECEMBER 22, 2020

The latest deals include a license agreement with San Diego-based Ligand Therapeutics , which has a subsidiary producing technology for neurological disorders. The license agreement, together with the biotech’s cash reserves, is enough to fund operations through 2023.

Licensing 52

Licensing Licensing Genetics Sales 52

pharmaphorum

OCTOBER 8, 2020

Doudna is serving as scientific advisor to Scribe, and its chief executive is Benjamin Oakes, who has been working on genome editing for most of his scientific career, starting out looking at a rival technology to CRISPR called zinc finger nucleases before working in Doudna’s lab at the University of California, Berkeley. Benjamin Oakes.

Gene Editing 69

Gene Editing Gene In-Vivo Clinical Trials 69

BioTech 365

SEPTEMBER 29, 2020

NEW YORK, LONDON, & PARIS–(BUSINESS WIRE)–#biopharmaceutical–Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum (..)

Genomics 40

Genomics Genome Licensing Licensing 40

Pharmaceutical Technology

MAY 15, 2023

BMS is a specialty biopharmaceutical company that is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Antibody 130

Antibody DNA Genomics Genome 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Existing compositions have proven effective but a complex landscape of intellectual property (IP) and licensing agreements make accessing these compositions complex for new parties when attempting to get to the clinic. Outlook The era of mRNA-based genomic medicines is on the horizon.

Bioassay 130

Bioassay RNA Development Drugs 130

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genomics Genome 52

XTalks

DECEMBER 13, 2023

Xoma’s unique approach involves acquiring future economic interests tied to pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotech companies. It is now progressing towards the submission of a Biologics License Application (BLA) by the end of 2023. million, compared to $1.1

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

OCTOBER 1, 2021

It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document. Chief technology officer Clive Brown is also sitting on a £10 million stake. The post Oxford Nanopore makes stellar debut on UK stock market appeared first on.

Marketing 52

Marketing Genomics Genome Business Development 52